Friday, July 10, 2026

pharma · Respiratory Syncytial Virus Infections · Asthma

MedImmune

MedImmune is a pharma organization headquartered in EU. Primary therapeutic focus areas include Respiratory Syncytial Virus Infections, Asthma, Influenza, Stage III Non-small Cell Lung Cancer, Chronic Obstructive Pulmona

Gaithersburg, USA HQ
1987 Founded
896 Employees
EMA registrant Type
Company details
Status
Public
HQ
Gaithersburg, USA
Founded
1987
Employees
896
Programs
9
Drugs
7
Patents
0
Clinical program

CAIV-T

Phase 2 · mab · Influenza

CAIV-T for Influenza is a Phase 2 program (mab) at MedImmune with 1 ClinicalTrials.gov record(s).

← All MedImmune projects Phase 2 mab completed

Internal code D153-P522

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
MedImmune
Phase
Phase 2
Modality
mab
Indication
Influenza
Status
completed
Trials
1